Ongoing and future clinical trials will further inform clinical decision-making for patients with advanced or metastatic HER2-low and HER2-ultralow breast cancer and provide information on optimal sequencing strategies for HER2- and TROP2-directed ADCs in these populations. This evidence concerns the gene TACSTD2 and breast cancer.